ATLN
ATLANTIC INTERNATIONAL CORP.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.90
+0.00%Year over year
Reported trailing growth
- Revenue
- +31.1%
- EBITDA
- +5.1%
- EBIT
- -84.7%
- EPS
- +63.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -0.4%
- EBITDA
- +61.4%
- EBIT
- —
- Net income
- +56.1%
- EPS
- +70.7%
- Free cash flow
- +26.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026